BlackRock Piles Into Renk Near a 52-Week Low as Analysts See Oversold Opportunity

Despite a 10% weekly slide and 50% below October highs, BlackRock raised its Renk stake to 4.44%. Analysts see the sell-off as overdone given a €6.9bn backlog and upgraded targets.

The gap between Renk’s operational strength and its share price has never been wider. The defence contractor’s stock touched a fresh 52-week low of €43.91 on Friday, shedding 2.65% on the day and a hefty 10.40% over the week. At those levels, the equity is trading roughly 50% below the highs struck last October, and the year-to-date decline now exceeds a fifth of its value.

Yet even as the sell-off intensifies, the world’s largest asset manager is quietly increasing its exposure. A regulatory filing shows BlackRock lifted its total voting rights stake from 3.63% to 4.44% in mid-May, with 2.95% held directly under German securities trading rules and the remainder attributed via instruments. The move comes during one of the weakest patches for the stock, suggesting that at least one institutional heavyweight is not ready to write off the company’s prospects.

The broader defence sector has taken a hit from mounting peace hopes surrounding the Ukraine conflict, and Renk has been caught in the crossfire. The stock had previously benefited heavily from a defence-spending narrative, and any de-escalation talk naturally undermines that premium. Analysts, however, argue the punishment has gone too far. MWB Research upgraded Renk from Hold to Buy with a €53 price target, explicitly calling the sell-off overdone. It pointed to cautious comments from Rheinmetall as the catalyst that dragged the entire sector lower — but stressed that Renk’s own order book tells a very different story.

That order book is indeed the company’s strongest card. First-quarter order intake climbed 6.1% year-on-year to €582.3 million, pushing the total backlog to a hefty €6.9 billion. Revenue rose to €283.6 million, while adjusted EBIT advanced 10.4% to €42.4 million, yielding an operating margin of 15.0%. Crucially, more than 90% of the full-year revenue target — above €1.5 billion — is already backed by firm contracts and framework agreements, giving management rare visibility in an otherwise volatile market.

The full-year outlook remains unchanged: adjusted EBIT in a range of €255 million to €285 million, with a longer-term revenue ambition of €2.8 billion to €3.2 billion by 2030. CEO Dr. Alexander Sagel, whose contract was recently extended to March 31, 2032, is expected to address how that backlog will convert into free cash flow when he presents at the International Investment Forum on May 20.

Wall Street remains constructive despite the price collapse. Deutsche Bank, Jefferies, Berenberg and JPMorgan collectively see an average price target of €72.50. Goldman Sachs is more cautious, cutting its target from €70 to €65 on May 14 while sticking with a Neutral rating. Warburg Research holds at €63. Even the upgraded MWB target of €53 implies roughly 21% upside from current levels.

Shareholders have a dividend boost to look forward to as well. The proposed payout of €0.58 per share represents a 38% increase on the prior year, and will be voted on at the virtual annual general meeting on June 10. That meeting also includes a proposed election of Dr. Klaus Richter as a new supervisory board member, set to take the chair, replacing Claus von Hermann who is stepping down at his own request.

For now, the stock remains pinned below all its key moving averages, a technical picture that will not improve until upcoming events provide a tangible catalyst. The Q2 results on August 6 will be the next major test of whether the solid operational performance can finally gain traction against the sector’s sentiment headwinds.